2024

1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

   Cancers, Vol. 16, Núm. 9

2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

   Future Oncology, Vol. 20, Núm. 13, pp. 799-809

3. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

   Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

4. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

   AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

5. Access to melanoma drugs in Spain: a cross-sectional survey

   Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

6. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

   Clinical and Translational Oncology

7. Accuracy of Smartwatch Electrocardiographic Recording in the Acute Coronary Syndrome Setting: Rationale and Design of the ACS WATCH II Study

   Journal of Clinical Medicine, Vol. 13, Núm. 2

8. Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial

   Intensive Care Medicine, Vol. 50, Núm. 2, pp. 247-257

9. Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not

   European Urology

10. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

11. Cardiovascular risk in young people with childhood onset systemic lupus erythematosus

    The Lancet Rheumatology

12. Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738

13. Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?

    Translational Andrology and Urology

14. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

15. Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry

    Pediatric Rheumatology , Vol. 22, Núm. 1

16. Clinical impact of remote heart failure management using the multiparameter ICD HeartLogic alert

    Revista Espanola de Cardiologia

17. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

18. Clinical practice guideline on the management of vestibular schwannoma

    Acta Otorrinolaringologica Espanola, Vol. 75, Núm. 2, pp. 108-128

19. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

20. Current landscape of gastrointestinal radiation oncology in Spain: a multicenter real-life survey and comparison with key clinical guidelines

    Reports of Practical Oncology and Radiotherapy, Vol. 29, Núm. 3, pp. 340-347